Glutamate is the most pervasive neurotransmitter in the central nervous system. Problems with how glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer’s, substance abuse, and traumatic brain injury. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers—measures of biological processes that provide information about the state of a disease or a patient’s response to treatment. Scientifically-validated glutamate biomarkers can streamline research, increase researchers’ understanding of how glutamate-related disorders function, and accelerate the development of methods to treat and prevent these disorders.
The IOM’s Forum on Neuroscience and Nervous System Disorders held a workshop June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of glutamate-related biomarkers. Participants discussed the most promising current and emerging technologies for discovering glutamate-related biomarkers, and identified gaps in current research. In addition, participants considered possible approaches to validating biomarkers and the barriers to implementing these biomarkers in a way that would accelerate drug development. This document summarizes the workshop.
Click here to view the meeting agenda and presentations.